USPTO serial 98330220
CENCORA
Reviewed by CopyMark Law Group
Status 819
- Filing date
- Status date
- Registration date
- —
- Examiner
- WELLS, KELLEY L
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CENCORA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Conshohocken, PA, US
Conshohocken, PA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Anita B. Polott
Anita B. Polott Morgan, Lewis & Bockius LLP1111 Pennsylvania Avenue, NWAttention: TMSUWashington, DC 20004-2541Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Scientific and technological services, namely, research and design in the field of new product design and scientific research in the field of pharmacovigilance, clinical data review, chemistry data evaluation; Scientific research and laboratory research, all in the field of pharmaceuticals, medicines and medical products; industrial analysis and research services, namely, laboratory research services relating to pharmaceuticals, pharmaceutical research services, and research and development of new products for others; consulting services for others in the field of design, planning, and implementation project management in the field of pharmaceuticals, medicines and medical products; pharmaceutical product evaluation; consultancy pertaining to pharmacology; consultancy relating to research and development in the field of therapeutics; consultancy relating to laboratory testing of materials; pharmaceutical products development; testing of pharmaceuticals; provision of information and data relating to medical and veterinary research and development; inspection of pharmaceuticals; information technology services for the pharmaceutical and healthcare industries, namely, information technology consulting services relating to computer network design, computer software design, information technology architecture and infrastructure, installation, maintenance and repair of computer software; quality control testing for others; materials testing and evaluation; product safety testing; consulting services for others in the field of design, planning, and implementation project management of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals, drug safety, clinical research, clinical testing and clinical trials; Scientific and technological services, namely, research and design in the field of pharmaceutical development, medical devices, and biopharmaceuticals; scientific, technological, medical and pharmaceutical research and development services; industrial analysis and research services in the field of pharmaceuticals, medical devices, and biopharmaceuticals; research and development of new products for others; pharmaceutical drug development services; research and development of pharmaceutical preparations; scientific, technological, medical research and pharmaceutical research services and analysis services for scientific and technological purposes; biological research; clinical research, namely, scientific research in the nature of conducting clinical trials for others; providing medical research and scientific research information; provision of scientific information in the nature of scientific surveys; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; scientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars, therapeutics; development of a web application software for entering and evaluating informative texts for pharmaceuticals and medical products, in particular instructions for use, package inserts, specialist information and for the provision of various documents; database services, namely, electronic storage of data in computer databases; conversion of data or documents from physical to electronic media; testing, inspection or research of pharmaceuticals and medicines; design, engineering, research, development and testing services in the field of pharmaceuticals, medical devices, and biopharmaceuticals; research in the field of gene therapy; consultancy relating to quality assurance services, namely, quality assurance, quality control, quality evaluation and analysis in the field of pharmaceuticals, pharmaceutical manufacturing, medical devices, and biopharmaceuticals; research services relating to scientific work; preparation of scientific research analyses and evaluations relating to pharmaceuticals, medical devices, and biopharmaceuticals; development of pharmaceutical preparations and medicines; scientific investigations for medical purposes; conducting early evaluations in the field of new pharmaceuticals; medical research laboratory services; computer services, namely, on-site management of information technology systems for the pharmaceutical and healthcare industries; scientific evaluation of the drugs of others to determine drug efficacy; research and development services for assessing the efficiency of pharmaceuticals; analysis and evaluation of product design for others; analysis and evaluation of product development for others; quality control and evaluation of goods of others to determine conformity with certification standards; quality testing of products for certification purposes; consulting and advice on drug safety and monitoring for product research and development purposes; consultancy services in regard to the development and approval process of therapeutic and diagnostic biological samples and chemical samples; consultancy services for others in the field of design, planning, implementation and project management of clinical trials, scientific pharmacovigilance research, pharmaceutical and biotechnology product development; consultancy services in the fields of biotechnology, pharmaceutical research and development, laboratory testing of materials and pharmacogenetics; research laboratory analysis services in the fields of pharmaceuticals and development of biotechnology products that are used for medical diagnosis and treatment of persons; Software as a service (SAAS) services featuring software for product development processes and regulatory compliance using artificial intelligence for machine learning in order to supporting decision making processes; Software as a service (SAAS) services featuring software using artificial intelligence for machine learning for supporting decision making processes; Software as a service (SAAS) services featuring software for collecting data related to clinical trials, drug development, and drug safety; Software as a service (SAAS) services, namely, automation software for collecting data related to clinical trials, drug development, and drug safety; providing online non-downloadable computer programs for data processing; providing online non-downloadable unified communications software for integrating software communications systems and software development tools; providing online non-downloadable assistive software for collecting data related to clinical trials, drug development, and drug safety | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 24, 2026 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jul 20, 2026 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jul 20, 2026 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jun 29, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jun 29, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 3, 2026 | IUAF | USE AMENDMENT FILED | — |
| Apr 3, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Oct 21, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 26, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 26, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 20, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 24, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 24, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 24, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 24, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 24, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 26, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 26, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 26, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 18, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 13, 2025 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Feb 13, 2025 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 13, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 13, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 13, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 12, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Nov 12, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Aug 13, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 25, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 8, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 26, 2023 | NWAP | NEW APPLICATION ENTERED | — |